Veracyte Inc (VCYT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.94B
Last updated: Nov 17, 2026 at 5:47 PM ET
Veracyte Inc (VCYT) Statistics
Veracyte (VCYT) has a market cap of $1.94B and an enterprise value of $1.74B. Its trailing P/E is 13.5x.
Total Valuation
Enterprise value is 9.97% below the market cap, as cash exceeds debt.
| Market Cap | $1.94B |
|---|---|
| Enterprise Value | $1.74B |
| Latest price (Nov 17, 2026) | $24.23 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.4x and 1.4x.
| P/E Ratio | 13.5x |
|---|---|
| Forward P/E | 12.4x |
| P/S Ratio | 3.4x |
| Forward P/S | 3.3x |
| P/B Ratio | 1.4x |
| P/TBV Ratio | 5.0x |
| P/FCF Ratio | 12.0x |
| P/OCF Ratio | 11.1x |
| PEG Ratio | 0.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 12.8x EBITDA and 10.9x free cash flow.
| EV / Earnings | 13.8x |
|---|---|
| EV / Sales | 3.0x |
| EV / EBITDA | 12.8x |
| EV / EBIT | 14.8x |
| EV / FCF | 10.9x |
Price Statistics
The stock is down 38.42% over 52 weeks and trades 41.52% below its 50-day average.
| Beta (1Y) | 3.19 |
|---|---|
| 52-Week Change | -38.42% |
| 1-Month Change | -44.68% |
| 3-Month Change | -42.57% |
| 6-Month Change | -41.88% |
| 5-Year Change | +4.45% |
| 10-Year Change | +588.84% |
| Total Return (1Y) | -38.42% |
| Total Return (3Y CAGR) | -1.36% |
| Total Return (5Y CAGR) | -11.84% |
| Return vs SPY (1Y) | -49.05% |
| Max Drawdown (1Y) | -60.32% |
| Max Drawdown (3Y) | -60.32% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.45 |
| 50-Day Average | $41.43 |
| 200-Day Average | $42.24 |
| 52-Week Range | $21.91 to $60.91 |
| RSI (14 Days) | 28.3 |
| Average Volume (20 Days) | 2.87M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.56x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.56x |
|---|---|
| Quick Ratio | 5.25x |
| Debt / Equity | 0.00x |
| Debt / EBITDA | 0.05x |
| Debt / FCF | 0.04x |
Returns and Efficiency
Return on invested capital is 8.21% over the last 12 months, against a 5-year average of 5.06%.
| Return on Equity (ROE) | 8.85% |
|---|---|
| Return on Assets (ROA) | 8.06% |
| Return on Invested Capital (ROIC) | 8.21% |
| Return on Capital Employed (ROCE) | 7.94% |
| ROE (5Y Average) | -2.06% |
| ROA (5Y Average) | -1.92% |
| ROIC (5Y Average) | 5.06% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 6.59x |
| Receivables Turnover | 10.49x |
| Cash Conversion Cycle | 70 days |
Scores
VCYT has an Altman Z-Score of 9.01, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 9.01 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $581.78M over the last 12 months is up 17.50% from the 12 months before.
| Revenue | $581.78M |
|---|---|
| Revenue Growth (YoY) | +17.50% |
| Gross Profit | $418.79M |
| Operating Income | $99.39M |
| Pretax Income | $118.25M |
| Net Income | $126.85M |
| EBITDA | $136.77M |
| EBIT | $118.25M |
| Reported EPS (TTM) | $1.80 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.08% of the $1.57B in total assets.
| Cash and Equivalents | $199.83M |
|---|---|
| Total Debt | $6.73M |
| Net Cash | $193.09M |
| Net Cash Per Share | $2.40 |
| Working Capital | $383.67M |
| Shareholder Equity | $1.43B |
| Book Value Per Share | $17.80 |
| Tangible Book Value | $392.81M |
| Tangible Book Per Share | $4.88 |
| Total Assets | $1.57B |
| Total Liabilities | $139.99M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $11.94M of capital spending, operating cash flow left $161.95M of free cash flow.
| Operating Cash Flow | $173.88M |
|---|---|
| Capital Expenditures | $11.94M |
| Free Cash Flow | $161.95M |
| FCF Per Share | $2.01 |
| Depreciation and Amortization | $24.58M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 17.08%, against a 5-year average of -12.03%.
| Gross Margin | 71.98% |
|---|---|
| Operating Margin | 17.08% |
| Pretax Margin | 20.33% |
| Net Margin | 21.80% |
| EBITDA Margin | 23.51% |
| EBIT Margin | 20.33% |
| FCF Margin | 27.84% |
| Gross Margin (5Y Average) | 65.19% |
| Operating Margin (5Y Average) | -12.03% |
| Net Margin (5Y Average) | -9.82% |
Growth
Revenue grew 20.37% a year over 3 years.
| Revenue Growth (3Y CAGR) | +20.37% |
|---|---|
| Revenue Growth (5Y CAGR) | +34.50% |
| Book Value Per Share Growth (2Y CAGR) | +6.14% |
| Tangible Book Per Share Growth (2Y CAGR) | +26.98% |
Dividends and Yields
VCYT does not pay a dividend. Its free cash flow yield is 8.30%.
| Earnings Yield | 7.41% |
|---|---|
| FCF Yield | 8.30% |
| Shareholder Yield | 0.00% |
Peer Position
Against 4 similar companies, VCYT has the lowest P/E.
P/E RatioPeer median 37.7x
P/S RatioPeer median 3.2x
ROICPeer median -5.77%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.43%
| P/E Ratio | 13.5x vs 37.7x median |
|---|---|
| P/S Ratio | 3.4x vs 3.2x median |
| ROIC | 8.21% vs -5.77% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +17.50% vs +10.43% median |
Analyst Forecast
Consensus estimates put revenue growth at 10.75% and EPS growth at -6.45% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +10.75% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -6.45% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VCYT
What is VCYT's market cap?
Veracyte has a market cap of $1.94B. Its enterprise value, which adds debt and subtracts cash, is $1.74B.
What is VCYT's P/E ratio?
Veracyte has a trailing P/E ratio of 13.5x and a forward P/E of 12.4x.
How many shares of VCYT are outstanding?
Veracyte has 80.50M shares outstanding. The count is up 2.26% from a year earlier.
Does VCYT pay a dividend?
No. Veracyte does not pay a dividend.
How much debt does VCYT have?
Veracyte has $6.73M of total debt and $199.83M of cash and equivalents, a net cash position of $193.09M.
VCYT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts